Study to Evaluate the Performance and Safety of Expedial and Compare it to Expanded Polytetrafluoroethylene (ePTFE) Vascular Access Grafts
Clinical Study Comparing Expedial and ePTFE Vascular Access Grafts
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33125
- Vascular and General Surgery
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70809
- Vascular Surgery Associates
-
-
New York
-
Bronx, New York, United States, 10461
- Montefiore Medical Center
-
Bronx, New York, United States, 10461
- Vascular Surgery
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
South Carolina
-
Bamberg, South Carolina, United States, 29003
- General Surgery
-
Greenville, South Carolina, United States, 29605
- South Carolina Associates for Cardiac and Vascular Disease; Greenville Hospital System
-
-
Texas
-
San Antonio, Texas, United States, 78206
- Peripheral Vascular Associates
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient has chronic renal failure and requires vascular access for hemodialysis
- Patient has given informed consent to participate in the trial and is willing to comply with the study protocol
- Patient is male or female, 18 years of age or older
- The vascular access graft can be placed in the upper extremity (forearm, including across the elbow, or upper arm)
- Patient is undergoing or will undergo hemodialysis at a hospital or hemodialysis center
- Patient has a vein 4 mm or larger to which the graft can be anastomosed
Exclusion Criteria:
- Patient is unable to comply with the study follow-up
- Patient has a known sensitivity to polyurethane or porcine heparin
- Patient has a previous vascular access graft implanted and it is not possible to place the study graft proximal to the existing device and no other sites are available
- Patient has an immunodeficiency syndrome
- Patient has a prior history of bacterial infection within 8 weeks of implantation of graft
- Patient has a severe coagulation disorder
- Patient has an elevated platelet count of greater than 1 million
- Patient has a history of heparin-induced thrombocytopenia syndrome (HIT)
- Patient is pregnant
- Patient has a fever greater than 100 degrees Fahrenheit
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Primary or assisted primary patency at 1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Secondary patency
|
|
Overall adverse event rate
|
|
Time to first access
|
|
Time to hemostasis following needle withdrawal after dialysis
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 00168
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.